UK families with Sanfilippo syndrome are struggling to access a newly approved gene therapy despite FDA approval of rebisufligene etisparvovec (Fayuvi), reported by the BBC and summarized in a report. The therapy is priced at roughly $4 million, and the article highlights uncertainty around eventual NHS access. The case underscores the continuing disconnect between regulatory clearance and national payer access, especially for high-cost AAV gene therapies for rare pediatric diseases.
Get the Daily Brief